Market Research Logo

Gastric Cancer - Pipeline Review, H2 2015

Gastric Cancer - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Gastric Cancer - Pipeline Review, H2 2015’, provides an overview of the Gastric Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastric Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Gastric Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Gastric Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Gastric Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Gastric Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Gastric Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Gastric Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Gastric Cancer Overview
Therapeutics Development
Gastric Cancer - Therapeutics under Development by Companies
Gastric Cancer - Therapeutics under Investigation by Universities/Institutes
Gastric Cancer - Pipeline Products Glance
Gastric Cancer - Products under Development by Companies
Gastric Cancer - Products under Investigation by Universities/Institutes
Gastric Cancer - Companies Involved in Therapeutics Development
Gastric Cancer - Therapeutics Assessment
Drug Profiles
Gastric Cancer - Recent Pipeline Updates
Gastric Cancer - Dormant Projects
Gastric Cancer - Discontinued Products
Gastric Cancer - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Gastric Cancer, H2 2015
Number of Products under Development for Gastric Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Development by Companies, H2 2015 (Contd..6)
Number of Products under Development by Companies, H2 2015 (Contd..7)
Number of Products under Development by Companies, H2 2015 (Contd..8)
Number of Products under Development by Companies, H2 2015 (Contd..9)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Development by Companies, H2 2015 (Contd..9)
Products under Development by Companies, H2 2015 (Contd..10)
Products under Development by Companies, H2 2015 (Contd..11)
Products under Development by Companies, H2 2015 (Contd..12)
Products under Development by Companies, H2 2015 (Contd..13)
Products under Investigation by Universities/Institutes, H2 2015
Gastric Cancer - Pipeline by AB Science SA, H2 2015
Gastric Cancer - Pipeline by AbbVie Inc., H2 2015
Gastric Cancer - Pipeline by AbGenomics International, Inc., H2 2015
Gastric Cancer - Pipeline by Advaxis, Inc., H2 2015
Gastric Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2015
Gastric Cancer - Pipeline by AlphaVax, Inc., H2 2015
Gastric Cancer - Pipeline by Ambrx, Inc., H2 2015
Gastric Cancer - Pipeline by Amgen Inc., H2 2015
Gastric Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2015
Gastric Cancer - Pipeline by Astellas Pharma Inc., H2 2015
Gastric Cancer - Pipeline by AstraZeneca Plc, H2 2015
Gastric Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015
Gastric Cancer - Pipeline by Azaya Therapeutics Incorporated, H2 2015
Gastric Cancer - Pipeline by Basilea Pharmaceutica AG, H2 2015
Gastric Cancer - Pipeline by Bayer AG, H2 2015
Gastric Cancer - Pipeline by BioMarin Pharmaceutical Inc., H2 2015
Gastric Cancer - Pipeline by Biotecnol, Inc., H2 2015
Gastric Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Gastric Cancer - Pipeline by Boston Biomedical, Inc., H2 2015
Gastric Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2015
Gastric Cancer - Pipeline by cCAM Biotherapeutics Ltd., H2 2015
Gastric Cancer - Pipeline by Celgene Corporation, H2 2015
Gastric Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2015
Gastric Cancer - Pipeline by Cellectar Biosciences, Inc., H2 2015
Gastric Cancer - Pipeline by Celltrion, Inc., H2 2015
Gastric Cancer - Pipeline by Celon Pharma Sp. z o.o., H2 2015
Gastric Cancer - Pipeline by Cerulean Pharma, Inc., H2 2015
Gastric Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2015
Gastric Cancer - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2015
Gastric Cancer - Pipeline by Curaxys, S.L., H2 2015
Gastric Cancer - Pipeline by DAE HWA Pharmaceutical Co., Ltd., H2 2015
Gastric Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Gastric Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2015
Gastric Cancer - Pipeline by DiaMedica Inc., H2 2015
Gastric Cancer - Pipeline by Dong-A Socio Group, H2 2015
Gastric Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H2 2015
Gastric Cancer - Pipeline by Eddingpharm, H2 2015
Gastric Cancer - Pipeline by EirGenix Inc., H2 2015
Gastric Cancer - Pipeline by Eli Lilly and Company, H2 2015
Gastric Cancer - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015
Gastric Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2015
Gastric Cancer - Pipeline by Exelixis, Inc., H2 2015
Gastric Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Gastric Cancer - Pipeline by Five Prime Therapeutics, Inc., H2 2015
Gastric Cancer - Pipeline by Galaxy Biotech, LLC, H2 2015
Gastric Cancer - Pipeline by Galena Biopharma, Inc., H2 2015
Gastric Cancer - Pipeline by Genelux Corporation, H2 2015
Gastric Cancer - Pipeline by Genentech, Inc., H2 2015
Gastric Cancer - Pipeline by Gilead Sciences, Inc., H2 2015
Gastric Cancer - Pipeline by GlaxoSmithKline Plc, H2 2015
Gastric Cancer - Pipeline by GlycoNex Inc., H2 2015
Gastric Cancer - Pipeline by Glycotope GmbH, H2 2015
Gastric Cancer - Pipeline by Green Cross Corporation, H2 2015
Gastric Cancer - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015
Gastric Cancer - Pipeline by Hutchison MediPharma Limited, H2 2015
Gastric Cancer - Pipeline by Ignyta, Inc., H2 2015
Gastric Cancer - Pipeline by ImmunoGen, Inc., H2 2015
Gastric Cancer - Pipeline by Immunomedics, Inc., H2 2015
Gastric Cancer - Pipeline by Incyte Corporation, H2 2015
Gastric Cancer - Pipeline by INSYS Therapeutics, Inc., H2 2015
Gastric Cancer - Pipeline by Intezyne, Inc, H2 2015
Gastric Cancer - Pipeline by ISU ABXIS Co.,Ltd., H2 2015
Gastric Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2015
Gastric Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H2 2015
Gastric Cancer - Pipeline by Johnson & Johnson, H2 2015
Gastric Cancer - Pipeline by Kadmon Corporation, LLC, H2 2015
Gastric Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
Gastric Cancer - Pipeline by Kinex Pharmaceuticals, LLC, H2 2015
Gastric Cancer - Pipeline by Kuhnil Pharmaceutical Co., Ltd., H2 2015
Gastric Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015
Gastric Cancer - Pipeline by LegoChem Biosciences, Inc, H2 2015
Gastric Cancer - Pipeline by Les Laboratoires Servier SAS, H2 2015
Gastric Cancer - Pipeline by MacroGenics, Inc., H2 2015
Gastric Cancer - Pipeline by Mebiopharm Co., Ltd., H2 2015
Gastric Cancer - Pipeline by Merck & Co., Inc., H2 2015
Gastric Cancer - Pipeline by Merck KGaA, H2 2015
Gastric Cancer - Pipeline by Mersana Therapeutics, Inc., H2 2015
Gastric Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Gastric Cancer - Pipeline by Molecular Targeting Technologies, Inc., H2 2015
Gastric Cancer - Pipeline by MSM Protein Technologies, Inc., H2 2015
Gastric Cancer - Pipeline by NanoCarrier Co., Ltd., H2 2015
Gastric Cancer - Pipeline by NeoPharm Co., Ltd., H2 2015
Gastric Cancer - Pipeline by Novartis AG, H2 2015
Gastric Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2015
Gastric Cancer - Pipeline by Oncobiologics, Inc., H2 2015
Gastric Cancer - Pipeline by Oncolys BioPharma Inc., H2 2015
Gastric Cancer - Pipeline by Oncolytics Biotech Inc., H2 2015
Gastric Cancer - Pipeline by OncoTherapy Science, Inc., H2 2015
Gastric Cancer - Pipeline by Oncothyreon Inc., H2 2015
Gastric Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
Gastric Cancer - Pipeline by Panacea Biotec Limited, H2 2015
Gastric Cancer - Pipeline by Patrys Limited, H2 2015
Gastric Cancer - Pipeline by Pfizer Inc., H2 2015
Gastric Cancer - Pipeline by Pharma Mar, S.A., H2 2015
Gastric Cancer - Pipeline by Pharmacyclics, Inc., H2 2015
Gastric Cancer - Pipeline by Priaxon AG, H2 2015
Gastric Cancer - Pipeline by Puma Biotechnology, Inc., H2 2015
Gastric Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2015
Gastric Cancer - Pipeline by Richter Gedeon Nyrt., H2 2015
Gastric Cancer - Pipeline by Sanofi, H2 2015
Gastric Cancer - Pipeline by Sareum Holdings Plc, H2 2015
Gastric Cancer - Pipeline by Sequella, Inc., H2 2015
Gastric Cancer - Pipeline by Siena Biotech S.p.A., H2 2015
Gastric Cancer - Pipeline by Sorrento Therapeutics, Inc., H2 2015
Gastric Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015
Gastric Cancer - Pipeline by Sunesis Pharmaceuticals, Inc., H2 2015
Gastric Cancer - Pipeline by Supratek Pharma Inc., H2 2015
Gastric Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2015
Gastric Cancer - Pipeline by Synthon Holdings BV, H2 2015
Gastric Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2015
Gastric Cancer - Pipeline by Takis S.r.l., H2 2015
Gastric Cancer - Pipeline by Teikoku Pharma USA, Inc., H2 2015
Gastric Cancer - Pipeline by Tesaro, Inc., H2 2015
Gastric Cancer - Pipeline by Transgene SA, H2 2015
Gastric Cancer - Pipeline by Vaxon Biotech, H2 2015
Gastric Cancer - Pipeline by Zhejiang BetaPharma Co., Ltd., H2 2015
Gastric Cancer - Pipeline by Zymeworks Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Gastric Cancer Therapeutics - Recent Pipeline Updates, H2 2015
Gastric Cancer - Dormant Projects, H2 2015
Gastric Cancer - Dormant Projects (Contd..2), H2 2015
Gastric Cancer - Dormant Projects (Contd..4), H2 2015
Gastric Cancer - Dormant Projects (Contd..6), H2 2015
Gastric Cancer - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Gastric Cancer, H2 2015
Number of Products under Development for Gastric Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report